Search

Displaying results 1441 - 1450 of 4234 in total
  1. Drug

    Amifampridine

    go.drugbank.com/drugs/DB11640
    Approved

    Firdapse (amifampridine) was formally approved by the US FDA for the treatment of adults with LEMS as recently as November of 2018 [L4819]. … Amifampridine phosphate is a more stable salt that serves as an active ingredient of EMA-approved Firdapse, which was previously marketed as Zenas.

  2. Drug

    Propiverine

    go.drugbank.com/drugs/DB12278
    Approved

    Propiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) . Overactive bladder (OAB) is a chronic condition of the lower urinary tract characterized...

  3. Drug

    Clobetasone

    go.drugbank.com/drugs/DB13158
    Approved

    Clobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions

  4. Drug

    Cilazapril

    go.drugbank.com/drugs/DB01340
    ApprovedInvestigational

    It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.

  5. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    [A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and … Ustekinumab biosimilars are available in some markets, including Wezlana,[L49071] Yesintek,[L52815] Selarsdi,[L52820] Otulfi,[L52825] and Pyzchiva[L52810] in the US, Jamteki (AVT04),[L49076] Steqeyma,[

  6. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 re...

  7. Drug

    Lornoxicam

    go.drugbank.com/drugs/DB06725
    ApprovedInvestigational

    Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of...

  8. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL).

  9. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic

  10. Drug

    Vanillyl butyl ether

    go.drugbank.com/drugs/DB11299
    Approved

    It is added to food products as a flavoring agent. … It is also present in cosmetics and personal care products as a fragrance ingredient, oral care agent, hair conditioning agent, and warming or cooling agent.